Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02981368 · ClinicalTrials.gov registry record · Phase 2
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
A Phase 2 study, sponsored by Progenics Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT02981368 is a Phase 2 study that has completed, run by Progenics Pharmaceuticals. The registered enrollment target is 385 participants.
The verdict
NCT02981368, a Phase 2 study, has completed, sponsored by Progenics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B). Cohort B is complete and no longer recruiting subjects.
Interventions
- DIAGNOSTIC_TEST PET/CT imaging
- DRUG 18F-DCFPyL Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02981368
The ClinicalTrials.gov registry entry for NCT02981368 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Progenics Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET/CT imaging is the first listed.
NCT02981368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02981368 about?
NCT02981368 is a clinical study titled "Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer". This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Coho...
What is the current status of trial NCT02981368?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2016-11. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02981368?
The interventions under investigation include: PET/CT imaging (DIAGNOSTIC_TEST), 18F-DCFPyL Injection (DRUG).
Who is sponsoring clinical trial NCT02981368?
This trial is sponsored by Progenics Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.